Lv4
550 积分 2023-04-11 加入
[China lymphoma diagnosis and treatment guideline (2026 edition)]
4天前
已完结
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial
1个月前
已完结
Pancreatic cancer
3个月前
已完结
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
5个月前
已完结
Obinutuzumab Treatment of Follicular Lymphoma
5个月前
已完结
[Job exposure matrices]
5个月前
已关闭
Occupation and risk of lymphoma: a multicentre prospective cohort study (EPIC)
5个月前
已完结
Polygenic Risk, Agent Orange Exposure, and Lymphoid Neoplasms in the Veterans Affairs Million Veteran Program
5个月前
已完结
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
5个月前
已完结
Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study
5个月前
已完结
皖公网安备34019202002308
